Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Merck & Co. is flexing its pharmaceutical muscles with strong dividend growth, steady cash flow, and a blockbuster cancer ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

Initiated Phase 1/2 combination study of micvotabart pelidotin and Merck's anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors. We aim to select a ...

Merck & Co. Inc. closed 29.59% below its 52-week high of $134.63, which the company reached on June 25th.

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free ...

Merck & Co. ranks among the top dividend contenders, having increased payouts for 14 consecutive years. Dividend stocks ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats. Trump ...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of its HPV vaccine Gardasil to patients and prescribers. A federal court ruled ...